AR117194A1 - Compuestos de anillos fusionados - Google Patents
Compuestos de anillos fusionadosInfo
- Publication number
- AR117194A1 AR117194A1 ARP190103302A ARP190103302A AR117194A1 AR 117194 A1 AR117194 A1 AR 117194A1 AR P190103302 A ARP190103302 A AR P190103302A AR P190103302 A ARP190103302 A AR P190103302A AR 117194 A1 AR117194 A1 AR 117194A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- alkoxy
- haloalkyl
- halo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 14
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 8
- 125000001475 halogen functional group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 5
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 abstract 5
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 5
- -1 C1−6 hydroxyalkanoyl Chemical group 0.000 abstract 4
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 4
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 125000005466 alkylenyl group Chemical group 0.000 abstract 3
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 3
- 125000005242 carbamoyl alkyl group Chemical group 0.000 abstract 3
- 125000004995 haloalkylthio group Chemical group 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 101710113436 GTPase KRas Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 102200006538 rs121913530 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este; caracterizado porque R¹ es un resto electrofílico capaz de formar un enlace covalente con un residuo de cisteína en la posición 12 de una proteína mutante K-Ras G12C; R² se selecciona del grupo que consiste en H, OH, NH₂, halo, alquilo C₁₋₆, haloalquilo C₁₋₆, ciclopropilo y -NHR, donde R se selecciona del grupo que consiste en alquilo C₁₋₆, alcoxi C₁₋₆, alcanoilo C₁₋₆, hidroxialcanoilo C₁₋₆, cianoalquilo C₁₋₆, alquilamino C₁₋₆, -(alquilenilo C₁₋₆)NH(CH₃)-(alquilenilo C₁₋₆)N(CH₃)₂ y -(alquilenilo C₁₋₃)(heterociclilo de 3 - 7 miembros); R³ y R⁴ se seleccionan cada uno independientemente del grupo que consiste en H, NH₂, halo, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, alquiltio C₁₋₆, haloalquiltio C₁₋₆, alquilamino C₁₋₆ y ciclopropilo; R⁵ se selecciona del grupo que consiste en H, NH₂, halo, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, alquiltio C₁₋₆, haloalquiltio C₁₋₆, alquilamino C₁₋₆ y cicloalquilo C₃₋₇, en donde al menos uno de R², R³, R⁴ y R⁵ es diferente de H; o R² y R³, R³ y R⁴, o R⁴ y R⁵, junto con los átomos a los cuales están unidos, forman un cicloalquilo C₃₋₇, heterocicloalquilo de 3 a 7 miembros, arilo C₆₋₁₄ o heteroarilo de 5 a 10 miembros; cada uno de los cuales está opcionalmente sustituido con 1 a 4 sustituyentes, en donde cada sustituyente se selecciona independientemente del grupo que consiste en OH, NH₂, halo, alquilo C₁₋₃, haloalquilo C₁₋₃, alcoxi C₁₋₃ y haloalcoxi C₁₋₃; X se selecciona del grupo que consiste en NH₂, alcoxi C₁₋₆, alquilo C₁₋₆, alquilamino C₁₋₆, alquilsulfanilo C₁₋₆, alquilsulfonilo C₁₋₆, alquiltio C₁₋₆, cicloalquilo C₃₋₇, heterociclilo de 4 a 7 miembros y heterociclilamino de 4 a 7 miembros; cada uno de los cuales está opcionalmente sustituido con 1 a 4 sustituyentes, en donde cada sustituyente se selecciona independientemente del grupo que consiste en OH, NH₂, halo, ciano, carboxi, carbamoilo, alquilo C₁₋₆, aminoalquilo C₁₋₆, carbamoilalquilo C₁₋₆, carboxialquilo C₁₋₆, cianoalquilo C₁₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆ y heterociclilo de 4 a 7 miembros; en donde dos sustituyentes geminales se pueden tomar juntos para formar espirocicloalquilo C₃₋₇ o espiroheterociclilo de 4 a 7 miembros; Y se selecciona del grupo que consiste en -L-Y¹ o Y¹; Y¹ se selecciona del grupo que consiste en H, NH₂, halo, ciano, carbamoilo, alquenilo C₂₋₆, alcoxi C₁₋₆, alquilo C₁₋₆, alquilo C₁₋₆ sustituido con un heterociclilo de 4 a 10 miembros que se sustituye opcionalmente con 1 - 4 sustituyentes Y¹ᵃ, alquilo C₁₋₆ sustituido con un sustituyente dialquilamino C₁₋₆, alquilo C₁₋₆ sustituido con un dialquilamino ciclopropilo C₁₋₆, alquilsulfanilo C₁₋₆, alquilsulfonilo C₁₋₆, alquiltio C₁₋₆, alquinilo C₂₋₆, alquilamino C₁₋₆, arilo C₆₋₁₄, arilo C₆₋₁₄ sustituido con un alquilo C₁₋₆, aminoalquilo C₁₋₆, carbamoilalquilo C₁₋₆, carboxialquilo C₁₋₆, cianoalquilo C₁₋₆, cicloalquilo C₃₋₇, cicloalquilo C₃₋₇ sustituido con un dialquilamino C₁₋₆, haloalcoxi C₁₋₆, haloalquilo C₁₋₆, heteroarilo de 5 a 10 miembros, heterociclilo de 4 a 10 miembros, un heterociclilo de 4 a 10 miembros sustituido con metilo, hidroxi y oxo; cada Y¹ᵃ se selecciona independientemente del grupo que consiste en halo, alquilo C₁₋₆, alcoxi C₁₋₆, heterociclilo de 3 a 7 miembros, alcoxi C₁₋₆alquilo C₁₋₆, haloalquilo C₁₋₆, oxo, hidroxi, NH₂, ciano, carboxialquilo C₁₋₆, cianoalquilo C₁₋₆, hidroxialquilo C₁₋₆ y haloalcoxi C₁₋₆; L se selecciona del grupo que consiste en un enlace, O, S y N(Lᵃ); Lᵃ se selecciona del grupo que consiste en hidrógeno y alquilo C₁₋₃; U es C(R⁶ᵃ); V es C(R⁶ᵇ); W es C(R⁶ᶜ) o N; cada uno de R⁶ᵃ, R⁶ᵇ y R⁶ᶜ se selecciona independientemente del grupo que consiste en H, OH, NH₂, halo, ciano, carbamoilo, alquenilo C₂₋₆, alcoxi C₁₋₆, alquilo C₁₋₆, alquilo C₁₋₆ sustituido con un sustituyente heterociclilo de 4 a 10 miembros, alquilsulfanilo C₁₋₆, alquilsulfonilo C₁₋₆, alquiltio C₁₋₆, haloalquiltio C₁₋₆, alquinilo C₂₋₆, alquilamino C₁₋₆, arilo C₆₋₁₄, aminoalquilo C₁₋₆, carbamoilalquilo C₁₋₆, carboxialquilo C₁₋₆, cianoalquilo C₁₋₆, cicloalquilo C₃₋₇, haloalcoxi C₁₋₆, haloalquilo C₁₋₆, heteroarilo de 5 a 10 miembros y heterociclilo de 4 a 10 miembros; y n se selecciona del grupo que consiste en 0, 1 y 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018114788 | 2018-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117194A1 true AR117194A1 (es) | 2021-07-21 |
Family
ID=69232886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103302A AR117194A1 (es) | 2018-11-09 | 2019-11-08 | Compuestos de anillos fusionados |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11236068B2 (es) |
| EP (1) | EP3735299A2 (es) |
| JP (3) | JP6941241B2 (es) |
| KR (2) | KR20230147742A (es) |
| CN (5) | CN118084867A (es) |
| AR (1) | AR117194A1 (es) |
| AU (3) | AU2019377130B2 (es) |
| BR (1) | BR112021008986A2 (es) |
| CA (1) | CA3087089C (es) |
| CL (2) | CL2021001171A1 (es) |
| CO (1) | CO2021005987A2 (es) |
| CR (1) | CR20210229A (es) |
| IL (2) | IL311187A (es) |
| MA (1) | MA51530A (es) |
| MX (1) | MX2021005428A (es) |
| MY (1) | MY196726A (es) |
| PE (1) | PE20211504A1 (es) |
| PH (1) | PH12021551065A1 (es) |
| SG (1) | SG11202103298QA (es) |
| TW (2) | TWI784209B (es) |
| UA (1) | UA127930C2 (es) |
| WO (1) | WO2020097537A2 (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021014096A (es) | 2019-05-21 | 2022-02-11 | Inventisbio Co Ltd | Compuestos heterociclicos, metodos de preparacion y usos de estos. |
| KR20220106980A (ko) | 2019-10-28 | 2022-08-01 | 머크 샤프 앤드 돔 코포레이션 | Kras g12c 돌연변이체의 소분자 억제제 |
| EP4065231A1 (en) * | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| MX2023001682A (es) * | 2020-08-12 | 2023-02-22 | Genentech Inc | Sintesis de compuestos de quinazolina. |
| JP2023541236A (ja) | 2020-09-03 | 2023-09-29 | レボリューション メディシンズ インコーポレイテッド | Ｓｈｐ２変異を有する悪性腫瘍を治療するためのｓｏｓ１阻害剤の使用 |
| EP4223761A1 (en) * | 2020-09-30 | 2023-08-09 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinazoline compound and application thereof |
| US20240034733A1 (en) * | 2020-11-03 | 2024-02-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| US20220152029A1 (en) * | 2020-11-13 | 2022-05-19 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer |
| MX2023005529A (es) * | 2020-11-13 | 2023-05-25 | Genentech Inc | Metodos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de vegf para tratar tumores solidos. |
| WO2022105855A1 (en) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| WO2022105857A1 (en) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| US20220193077A1 (en) * | 2020-12-08 | 2022-06-23 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors |
| US20240109893A1 (en) * | 2020-12-22 | 2024-04-04 | Shanghai Kechow Pharma, Inc. | Preparation and application method of heterocyclic compounds as kras inhibitor |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| CA3207854A1 (en) * | 2021-02-09 | 2022-08-18 | Liansheng Li | Heterocyclic compounds and uses thereof |
| WO2022171018A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州泽璟生物制药股份有限公司 | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 |
| WO2022171013A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | 四氢喹唑啉类化合物 |
| MX2023009135A (es) * | 2021-02-09 | 2023-08-16 | Genentech Inc | Compuestos de oxazepina tetraciclica y usos de estos. |
| AU2022224511A1 (en) * | 2021-02-16 | 2023-08-10 | Lawrence Livermore National Security, Llc | Compositions and methods for inhibition of ras |
| WO2022214102A1 (zh) * | 2021-04-09 | 2022-10-13 | 杭州英创医药科技有限公司 | 作为kras g12d抑制剂的杂环化合物 |
| WO2022221386A1 (en) * | 2021-04-14 | 2022-10-20 | Erasca, Inc. | Selective kras inhibitors |
| EP4322954A1 (en) * | 2021-04-16 | 2024-02-21 | Merck Sharp & Dohme LLC | Small molecule inhibitors of kras g12d mutant |
| EP4340883A1 (en) * | 2021-05-19 | 2024-03-27 | Genentech, Inc. | Combination therapy |
| WO2022247760A1 (zh) * | 2021-05-22 | 2022-12-01 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物，及其制备和治疗用途 |
| WO2022251496A1 (en) * | 2021-05-26 | 2022-12-01 | Cornell University | Rigidified macrocycles, complexes with radionuclides, and use in targeted radiotherapy of cancer |
| TW202325284A (zh) * | 2021-08-18 | 2023-07-01 | 大陸商北京加科思新藥研發有限公司 | N-環丙基吡啶并[4,3-d]嘧啶-4-胺衍生物及其用途 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| US20230203062A1 (en) | 2021-11-24 | 2023-06-29 | Genentech, Inc. | Therapeutic compounds and methods of use |
| TW202332429A (zh) | 2021-11-24 | 2023-08-16 | 美商建南德克公司 | 治療性化合物及其使用方法 |
| WO2023097227A1 (en) * | 2021-11-24 | 2023-06-01 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras mutated proteins |
| WO2023122662A1 (en) | 2021-12-22 | 2023-06-29 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| WO2023133181A1 (en) * | 2022-01-06 | 2023-07-13 | Theras, Inc. | Kras inhibitors |
| WO2023133183A1 (en) * | 2022-01-06 | 2023-07-13 | Theras, Inc. | Kras inhibitors |
| WO2023150706A1 (en) * | 2022-02-07 | 2023-08-10 | Genentech, Inc. | Solid forms of 1-((s)-4-((r)-7-(6-amino-4-methyl-3- (trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((s)-1- methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3- methylpiperazin-1-yl)prop-2-en-1-one |
| WO2023150653A1 (en) * | 2022-02-07 | 2023-08-10 | Genentech, Inc. | Process for synthesis of quinazoline compounds |
| CN115043729A (zh) * | 2022-07-04 | 2022-09-13 | 青岛大学 | 一种2,2’-二氟联芳基化合物的不对称合成方法 |
| WO2024036270A1 (en) | 2022-08-11 | 2024-02-15 | Bristol-Myers Squibb Company | Kras inhibitors |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024112654A1 (en) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| CN115920658B (zh) * | 2023-01-15 | 2023-10-20 | 安徽科博瑞环境科技有限公司 | 低表面能抗污染中空纤维膜及其制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002557A1 (en) | 1997-07-11 | 1999-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V | Novel pharmaceutically active compounds interacting with gtp-binding proteins |
| AU2009259853A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine JAK inhibitor compounds and methods |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| EP3055290B1 (en) * | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| ES2826443T3 (es) | 2014-09-25 | 2021-05-18 | Araxes Pharma Llc | Inhibidores de proteínas mutantes KRAS G12C |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| MX2017012979A (es) | 2015-04-10 | 2017-11-28 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y metodos de uso de los mismos. |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| MX2018013983A (es) | 2016-05-18 | 2019-08-16 | Mirati Therapeutics Inc | Inhibidores g12c de kras. |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| EP3630747A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| WO2018218071A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
| JP2020521742A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | Ｋｒａｓの共有結合性阻害剤 |
| ES2944547T3 (es) | 2017-11-15 | 2023-06-22 | Mirati Therapeutics Inc | Inhibidores de KRas G12C |
| JP2021506862A (ja) | 2017-12-19 | 2021-02-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
-
2019
- 2019-11-08 UA UAA202101478A patent/UA127930C2/uk unknown
- 2019-11-08 KR KR1020237033977A patent/KR20230147742A/ko active Application Filing
- 2019-11-08 EP EP19842848.4A patent/EP3735299A2/en active Pending
- 2019-11-08 AU AU2019377130A patent/AU2019377130B2/en active Active
- 2019-11-08 CR CR20210229A patent/CR20210229A/es unknown
- 2019-11-08 AR ARP190103302A patent/AR117194A1/es unknown
- 2019-11-08 JP JP2020542808A patent/JP6941241B2/ja active Active
- 2019-11-08 TW TW108140719A patent/TWI784209B/zh active
- 2019-11-08 US US16/679,104 patent/US11236068B2/en active Active
- 2019-11-08 WO PCT/US2019/060578 patent/WO2020097537A2/en active Application Filing
- 2019-11-08 BR BR112021008986-1A patent/BR112021008986A2/pt unknown
- 2019-11-08 MX MX2021005428A patent/MX2021005428A/es unknown
- 2019-11-08 KR KR1020207024122A patent/KR102587544B1/ko active IP Right Grant
- 2019-11-08 TW TW111140273A patent/TW202325703A/zh unknown
- 2019-11-08 PE PE2021000682A patent/PE20211504A1/es unknown
- 2019-11-08 CN CN202410280943.8A patent/CN118084867A/zh active Pending
- 2019-11-08 CN CN202410281087.8A patent/CN118084870A/zh active Pending
- 2019-11-08 SG SG11202103298QA patent/SG11202103298QA/en unknown
- 2019-11-08 IL IL311187A patent/IL311187A/en unknown
- 2019-11-08 CA CA3087089A patent/CA3087089C/en active Active
- 2019-11-08 MA MA051530A patent/MA51530A/fr unknown
- 2019-11-08 CN CN202410280860.9A patent/CN118084866A/zh active Pending
- 2019-11-08 CN CN201980026181.6A patent/CN112105419B/zh active Active
- 2019-11-08 IL IL282916A patent/IL282916B1/en unknown
- 2019-11-08 MY MYPI2021002582A patent/MY196726A/en unknown
- 2019-11-08 CN CN202410281112.2A patent/CN118084868A/zh active Pending
-
2021
- 2021-05-04 CL CL2021001171A patent/CL2021001171A1/es unknown
- 2021-05-07 CO CONC2021/0005987A patent/CO2021005987A2/es unknown
- 2021-05-07 PH PH12021551065A patent/PH12021551065A1/en unknown
- 2021-07-15 JP JP2021116809A patent/JP7374960B2/ja active Active
- 2021-12-17 US US17/644,993 patent/US20230089126A1/en active Pending
-
2022
- 2022-03-01 AU AU2022201413A patent/AU2022201413B9/en active Active
- 2022-03-22 CL CL2022000698A patent/CL2022000698A1/es unknown
-
2023
- 2023-10-25 JP JP2023183500A patent/JP2024023189A/ja active Pending
-
2024
- 2024-02-13 AU AU2024200904A patent/AU2024200904A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117194A1 (es) | Compuestos de anillos fusionados | |
| AR115978A1 (es) | Compuesto con anillos fusionados | |
| AR095706A1 (es) | Indazoles sustituidos con heteroarilo | |
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR108875A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR108325A1 (es) | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas | |
| AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR127309A2 (es) | Derivados de piridazinona | |
| AR101265A1 (es) | Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble | |
| AR113929A1 (es) | Compuestos heterocíclicos | |
| AR095708A1 (es) | Indazoles sustituidos con diaminoheteroarilo | |
| AR116109A1 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| AR100160A1 (es) | 1H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS Y PIRAZOLO[3,4-c]PIRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEÍNAS BET | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR094857A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
| AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR091208A1 (es) | Derivados de piperidina | |
| AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| AR110026A1 (es) | Inhibidores de pde2 | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 |